59,286 Shares in Organon & Co. (NYSE:OGN) Acquired by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. purchased a new position in shares of Organon & Co. (NYSE:OGNGet Rating) in the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 59,286 shares of the company’s stock, valued at approximately $56,000.

Several other institutional investors have also made changes to their positions in the stock. Trustcore Financial Services LLC boosted its holdings in shares of Organon & Co. by 14.7% during the first quarter. Trustcore Financial Services LLC now owns 2,361 shares of the company’s stock worth $82,000 after purchasing an additional 303 shares during the period. Radnor Capital Management LLC raised its position in Organon & Co. by 0.5% during the first quarter. Radnor Capital Management LLC now owns 61,566 shares of the company’s stock valued at $2,151,000 after acquiring an additional 314 shares in the last quarter. Roberts Glore & Co. Inc. IL raised its position in Organon & Co. by 1.1% during the first quarter. Roberts Glore & Co. Inc. IL now owns 29,118 shares of the company’s stock valued at $1,017,000 after acquiring an additional 327 shares in the last quarter. FourThought Financial LLC raised its position in Organon & Co. by 31.7% during the first quarter. FourThought Financial LLC now owns 1,442 shares of the company’s stock valued at $50,000 after acquiring an additional 347 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its position in Organon & Co. by 1.1% during the first quarter. Mutual of America Capital Management LLC now owns 33,808 shares of the company’s stock valued at $1,181,000 after acquiring an additional 361 shares in the last quarter. 76.28% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OGN has been the topic of several recent research reports. Piper Sandler raised shares of Organon & Co. from a “neutral” rating to an “overweight” rating and cut their price objective for the company from $37.00 to $34.00 in a research report on Tuesday, September 6th. Morgan Stanley cut their price objective on shares of Organon & Co. from $35.00 to $34.00 and set an “equal weight” rating on the stock in a research report on Friday, July 8th. Finally, Bank of America lowered shares of Organon & Co. from a “buy” rating to a “neutral” rating and cut their price objective for the company from $40.00 to $37.00 in a research report on Friday, August 5th.

Organon & Co. Stock Down 1.9 %

NYSE:OGN opened at $26.29 on Friday. Organon & Co. has a 12 month low of $26.20 and a 12 month high of $39.47. The firm has a market cap of $6.69 billion, a price-to-earnings ratio of 6.06 and a beta of 0.55. The company’s 50 day moving average is $30.34 and its 200-day moving average is $33.27.

Organon & Co. (NYSE:OGNGet Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.09. Organon & Co. had a net margin of 17.42% and a negative return on equity of 109.70%. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.50 billion. Research analysts predict that Organon & Co. will post 5.08 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 15th. Stockholders of record on Monday, August 15th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 4.26%. The ex-dividend date of this dividend was Friday, August 12th. Organon & Co.’s dividend payout ratio is 25.81%.

About Organon & Co.

(Get Rating)

Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.

See Also

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNGet Rating).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.